| 噻唑烷二酮类药物对骨骼的影响及其机制 |
| |
| 引用本文： | 韩桂艳,邢小平,李梅. 噻唑烷二酮类药物对骨骼的影响及其机制[J]. 国际内分泌代谢杂志, 2008, 28(4) |
| |
| 作者姓名： | 韩桂艳 邢小平 李梅 |
| |
| 作者单位： | 中国医学科学院,中国协和医科大学,北京协和医院内分泌科,卫生部内分泌重点实验室,北京,100730 |
| |
| 摘 要： | 噻唑烷二酮类(TZDs)药物是一种过氧化物酶体增殖物活化受体(PPAR)-γ激动剂,可减轻胰岛素抵抗,降低血糖,在2型糖尿病的治疗中发挥重要作用.动物实验显示其可抑制成骨细胞分化,降低骨形成,从而减少骨量.临床研究也显示其可降低患者骨密度,增加骨折发生率.其降低骨量的机制目前尚不明确,考虑与如下因素有关:降低Runt相关转录因子(Runx)2和osrerix的表达,抑制成骨细胞分化;下调其他与骨形成相关的细胞因子及信号分子的表达;抑制骨钙素基因的表达;加速成骨细胞凋亡.
|
| 关 键 词： | PPAR-γ 噻唑烷二酮 骨量减少 |
Effects of thiazolidinediones on bone mass and its mechanism |
| |
| HAN Gui-yan,XING Xiao-ping,LI Mei. Effects of thiazolidinediones on bone mass and its mechanism[J]. International JOurnal of Endocrinology and Metabolism, 2008, 28(4) |
| |
| Authors: | HAN Gui-yan XING Xiao-ping LI Mei |
| |
| Abstract: | Thiazolidinediones (TZDs) are ligands of peroxisome proliferators-activated receptor (PPAR)-γ.In vhro studys show that activation of PPAR-γ by TZDs caused increase of bone marrow adiposity and decrease of osteoblastogenesis,therefore resulted in bone loss.The Health,Aging,and Body Composition (Health ABC) study and A Diabetes Outcome Progression Trial (ADOPT) demonstrate that TZDs can reduce bone mineral density and increase the bone fracture rate in limbs.The molecular mechanisms remained unclear,they maybe relate to:PPAR-γ inhibits osteogenesis indirectely by reducing the expression of Runx2 and osreris;downregulates cytokines and signal molecules related to osteogenesis;inhibits the expression of osteocalcin gene,stimulates apoptosis of osteoblast. |
| |
| Keywords: | PPAR-γ Thiazolidinediones Bone loss |
| 本文献已被 万方数据 等数据库收录！ |
|
